Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Maybe Today Maybe Tomorrow Who Knows !!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(27)
•••
Comment by PTBaileyon Feb 08, 2022 9:24am
61 Views
Post# 34408025

RE:Maybe Today Maybe Tomorrow Who Knows !!!

RE:Maybe Today Maybe Tomorrow Who Knows !!!I didn't take the fishing comment way, maybe not a good word choice, I took it as looking for something that was missed or overlooked from past NR etc.

And you are correct he is another investor like the rest of us, with one difference, he has Bob's ear, so it could be just his take or it could also be what he knows from talking with Bob.

I don't know any other investor who is in touch, or speaks with Bob on a regular basis like he does. If anyone does they can let us know, I have only spoked to him about 5 or 6 time. So this puts him closer to the source to get more clarity, while not actually providing insider info.

I like getting feedback from people closest to the source. Is he right all the time? No, but neither has the company been rigtht all the time, so one can only put out what they know at the present or are being told. This company is somewht like Covid regulations, the science keeps changing. LOL, JMHO
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities